Rhode Island Medicaid and semaglutide
We could not read Rhode Island Medicaid's own notice, so its coverage of Wegovy and Zepbound for weight loss is not confirmed. KFF listed it as covering them in January 2026, a dated secondary source. A Rhode Island health plan says the state's fiscal 2027 budget ended this coverage, effective October 1, 2026, so that change may have taken effect.
In 2025 Rhode Island Medicaid paid for 29,679 semaglutide prescriptions (Ozempic, Wegovy, Rybelsus), 64% of its GLP-1 prescriptions and 32nd of the 50 states and DC. It reimbursed $31.2 million before rebates, $1,052 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 21,489 | $21.0 million | $977 |
| Wegovy | 6,899 | $9.0 million | $1,300 |
| Rybelsus | 1,291 | $1.3 million | $973 |
Rhode Island plans and prescribing rules
State of Rhode Island Anchor Plan (active employees). Rhode Island's Anchor Plan benefit booklet for active state employees, administered by Blue Cross & Blue Shield of Rhode Island, excludes prescribed weight-loss drugs unless they are a listed covered service or come through a program offered with the plan.
Semaglutide in the states around Rhode Island
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Rhode Island | 19 | $39/moWellmedr | 29,679 | Medicaid Wegovy: Not confirmed (KFF) |
| Connecticut | 19 | $39/moWellmedr | 107,061 | Medicaid Wegovy: No |
| Massachusetts | 18 | $39/moWellmedr | 53,347 | Medicaid Wegovy: No |



